Search Results
Aug 21, 2026, 12:34 ET /C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/
multimedia:https://www.prnewswire.com/news-releases/immunitybio-inc-ibrx-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit--contact-kessler-topaz-meltzer--check-llp-302856964.htmlSOURCE
More news about: Kessler Topaz Meltzer & Check, LLP
May 29, 2026, 09:00 ET The $13 Million Company Teaching the Immune System to Hunt Cancer
therapy is a crowded, well-funded field — and the contrast in scale is the entire investment argument.ImmunityBio (NASDAQ: IBRX) is the proof of concept that NK-cell immunotherapy can reach the market. Its NK-activating therapy ANKTIVA is FDA-approved for bladder cancer, the company
More news about: USA News Group
May 26, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX
May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: The Gross Law Firm
May 26, 2026, 04:52 ET IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected], Inc. (IBRX) Securities Class Action: ImmunityBio
More news about: Hagens Berman Sobol Shapiro LLP
May 23, 2026, 19:37 ET IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the
More news about: THE ROSEN LAW FIRM, P. A.
May 23, 2026, 09:41 ET ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
IBRX Investors with Losses Encouraged to Contact the Firm BeforeMay 26th DeadlineSAN FRANCISCO, May 23, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action
More news about: Hagens Berman Sobol Shapiro LLP
May 22, 2026, 13:09 ET Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
May 22, 2026, 12:00 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 26, 2026 (LEAD PLAINTIFF DEADLINE) TO
More news about: Law Offices of Howard G. Smith
May 21, 2026, 17:18 ET INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"), have until Tuesday, May 26, 2026 to seek appointment
More news about: Robbins Geller Rudman & Dowd LLP
May 21, 2026, 15:10 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected]
More news about: Pomerantz LLP
May 21, 2026, 09:14 ET IBRX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
May 21, 2026, 09:00 ET ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
IBRX Investors with Losses Encouraged to Contact the Firm BeforeMay 26th DeadlineSAN FRANCISCO, May 21, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action
More news about: Hagens Berman Sobol Shapiro LLP
May 19, 2026, 15:47 ET ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IBRX) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 19, 2026, 09:00 ET Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
May 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: The Gross Law Firm
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ: GTBP), Fate Therapeutics, Inc. (NASDAQ: FATE), Nkarta, Inc. (NASDAQ: NKTX), ImmunityBio, Inc. (NASDAQ: IBRX), INmune Bio, Inc. (NASDAQ: INMB)SAN FRANCISCO, May 19, 2026 /PRNewswire/
More news about: Equity Insider
May 18, 2026, 14:56 ET ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the
More news about: The Rosen Law Firm, P.A.
May 18, 2026, 12:21 ET IBRX 8-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
May 15, 2026, 22:00 ET ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive
More news about: ClaimsFiler
May 14, 2026, 21:53 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immunitybio-inc-of-class-action-lawsuit-and-upcoming-deadlines--ibrx-302773059.htmlSOURCE
More news about: Pomerantz LLP
May 14, 2026, 16:35 ET ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (
More news about: Kessler Topaz Meltzer & Check, LLP
May 14, 2026, 14:24 ET IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected], Inc. (IBRX) Securities Class Action: ImmunityBio
More news about: Hagens Berman Sobol Shapiro LLP
May 14, 2026, 10:24 ET IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
(NASDAQ: GTBP), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), Fate Therapeutics, Inc. (NASDAQ: FATE), ImmunityBio, Inc. (NASDAQ: IBRX), Coherus Oncology, Inc. (NASDAQ: CHRS).
More news about: Market News Updates
May 14, 2026, 03:23 ET ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during the class period listed are encouraged
More news about: DJS Law Group LLP
May 14, 2026, 03:23 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm